Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
GreenLight Biosciences Holdings PBC (GRNA) Stock Price & Overview
NASDAQ:GRNA • US39536G1058
Current stock price
0.2995 USD
0 (-0.03%)
At close:
0.2995 USD
0 (0%)
After Hours:
The current stock price of GRNA is 0.2995 USD. Today GRNA is down by -0.03%. In the past month the price increased by 1.49%. In the past year, price decreased by -85.53%.
GRNA Key Statistics
52-Week Range0.1768 - 5.8999
Current GRNA stock price positioned within its 52-week range.
1-Month Range0.2902 - 0.304
Current GRNA stock price positioned within its 1-month range.
- Market Cap
- 45.428M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.14
- Dividend Yield
- N/A
GRNA Stock Performance
Today
-0.03%
1 Week
+0.84%
1 Month
+1.49%
3 Months
-15.71%
Longer-term
6 Months -72.77%
1 Year -85.53%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
GRNA Stock Chart
GRNA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRNA. When comparing the yearly performance of all stocks, GRNA is a bad performer in the overall market: 95.46% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
GRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRNA. Both the profitability and financial health of GRNA have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GRNA Earnings
Next Earnings DateAug 14, 2023
Last Earnings DateMay 11, 2023
PeriodQ1 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 274.51%
GRNA Forecast & Estimates
7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.
For the next year, analysts expect an EPS growth of 26.28% and a revenue growth 167.93% for GRNA
Analysts
Analysts45.71
Price Target0.46 (53.59%)
EPS Next Y26.28%
Revenue Next Year167.93%
GRNA Financial Highlights
Over the last trailing twelve months GRNA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS decreased by -5.79% compared to the year before.
Income Statements
Revenue(TTM)10.34M
Net Income(TTM)-157.32M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.49 |
Chartmill High Growth Momentum
EPS Q2Q%44.19%
Sales Q2Q%1386.38%
EPS 1Y (TTM)-5.79%
Revenue 1Y (TTM)577.34%
GRNA Ownership
Ownership
Inst Owners0.03%
Shares151.68M
Float46.89M
Ins Owners16.91%
Short Float %N/A
Short RatioN/A
GRNA Industry Overview
GRNA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
GRNA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRNA
Company Profile
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
Company Info
IPO: 2021-01-14
GreenLight Biosciences Holdings PBC
29 Hartwell Avenue
Lexington MASSACHUSETTS US
Employees: 262
Phone: 16176168188.0
GreenLight Biosciences Holdings PBC / GRNA FAQ
What does GreenLight Biosciences Holdings PBC do?
GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Lexington, Massachusetts and currently employs 262 full-time employees. The company went IPO on 2021-01-14. The firm has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The firm's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. The company has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The firm's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.
What is the current price of GRNA stock?
The current stock price of GRNA is 0.2995 USD. The price decreased by -0.03% in the last trading session.
What is the dividend status of GreenLight Biosciences Holdings PBC?
GRNA does not pay a dividend.
What is the ChartMill rating of GreenLight Biosciences Holdings PBC stock?
GRNA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in GreenLight Biosciences Holdings PBC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRNA.
What is the market capitalization of GRNA stock?
GreenLight Biosciences Holdings PBC (GRNA) has a market capitalization of 45.43M USD. This makes GRNA a Nano Cap stock.
What is the ownership structure of GreenLight Biosciences Holdings PBC (GRNA)?
You can find the ownership structure of GreenLight Biosciences Holdings PBC (GRNA) on the Ownership tab.